{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:10:16Z","timestamp":1771654216482,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s42000-021-00343-w","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T04:26:47Z","timestamp":1641529607000},"page":"171-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment"],"prefix":"10.1007","volume":"21","author":[{"given":"Themistoklis","family":"Tzotzas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Goropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Karras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Terzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Siolos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argyrios","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Zaramboukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stelios","family":"Tigas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"343_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(77)91414-3","volume":"1","author":"RL Reddick","year":"1977","unstructured":"Reddick RL, Costa JC, Marx SJ (1977) Parathyroid hyperplasia and parathyromatosis. Lancet 1:549. https:\/\/doi.org\/10.1016\/S0140-6736(77)91414-3","journal-title":"Lancet"},{"issue":"6","key":"343_CR2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.metabol.2011.11.001","volume":"61","author":"MP Hage","year":"2012","unstructured":"Hage MP, Salti I, El-Hajj Fuleihan G (2012) Parathyromatosis: a rare yet problematic etiology of recurrent and persistent hyperparathyroidism. Metabolism 61(6):762\u201375. https:\/\/doi.org\/10.1016\/j.metabol.2011.11.001","journal-title":"Metabolism"},{"issue":"1","key":"343_CR3","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.4158\/EP13053.CR","volume":"20","author":"AB Scorza","year":"2014","unstructured":"Scorza AB, Moore AG, Terry M, Bricker LA (2014) Secondary parathyromatosis in a patient with normal kidney function: review of diagnostic modalities and approaches to management. Endocr Pract 20(1):e4-7. https:\/\/doi.org\/10.4158\/EP13053.CR","journal-title":"Endocr Pract"},{"issue":"2","key":"343_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/cncr.22790","volume":"110","author":"GG Fernandez-Ranvier","year":"2007","unstructured":"Fernandez-Ranvier GG, Khanafshar E, Jensen K, Zarnegar R, Lee J, Kebebew E, Duh QY, Clark OH (2007) Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer 110(2):255\u2013264. https:\/\/doi.org\/10.1002\/cncr.22790","journal-title":"Cancer"},{"issue":"8","key":"343_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fendo.2017.00079.eCollection","volume":"20","author":"JL Leere","year":"2017","unstructured":"Leere JL, Karmisholt J, Robaczyk M et al (2017) Contemporary medical management of primary hyperparathyroidism: a systematic review. Front Endocrinol 20(8):79. https:\/\/doi.org\/10.3389\/fendo.2017.00079.eCollection","journal-title":"Front Endocrinol"},{"issue":"5","key":"343_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4158\/EP14410.OR","volume":"21","author":"A Fountas","year":"2015","unstructured":"Fountas A, Andrikoula M, Giotaki Z, Limniati C, Tsakiridou E, Tigas S, Tsatsoulis A (2015) The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia. Endocr Pract 21(5):468\u2013473. https:\/\/doi.org\/10.4158\/EP14410.OR","journal-title":"Endocr Pract"},{"issue":"1","key":"343_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/qjmed\/hcw206","volume":"110","author":"A Fountas","year":"2017","unstructured":"Fountas A, Tigas S, Tsatsoulis A (2017) Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia. QJM 110(1):53\u201354. https:\/\/doi.org\/10.1093\/qjmed\/hcw206","journal-title":"QJM"},{"key":"343_CR8","doi-asserted-by":"publisher","unstructured":"Schulte JJ, Pease G, Taxy JB et al (2021) Distinguishing parathyromatosis, atypical parathyroid adenomas, and parathyroid carcinomas utilizing histologic and clinical features. Head Neck Pathol. https:\/\/doi.org\/10.1007\/s12105-020-01281-6","DOI":"10.1007\/s12105-020-01281-6"},{"issue":"5","key":"343_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/ndtplus\/sfr075","volume":"4","author":"C Vulpio","year":"2011","unstructured":"Vulpio C, D\u2019Errico G, Mattoli MV, Bossola M, Lodoli C, Fadda G, Bruno I, Giordano A, Castagneto M (2011) Recurrent renal hyperparathyroidism due to parathyromatosis. NDT Plus 4(5):318\u2013320. https:\/\/doi.org\/10.1093\/ndtplus\/sfr075","journal-title":"NDT Plus"},{"issue":"7","key":"343_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/imj.12185","volume":"43","author":"IW Sim","year":"2013","unstructured":"Sim IW, Farrell S, Grodski S, Jung C, Ng KW (2013) Parathyromatosis following spontaneous rupture of a parathyroid adenoma: natural history and the challenge of management. Intern Med J 43(7):819\u2013822. https:\/\/doi.org\/10.1111\/imj.12185","journal-title":"Intern Med J"},{"key":"343_CR11","doi-asserted-by":"publisher","first-page":"115048","DOI":"10.1016\/j.bone.2019.115048","volume":"129","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Makras P, Tournis S, Anastasilakis AD (2019) Off-label uses of denosumab in metabolic bone diseases. Bone 129:115048. https:\/\/doi.org\/10.1016\/j.bone.2019.115048","journal-title":"Bone"},{"issue":"18","key":"343_CR12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/jnci\/djt225","volume":"105","author":"MI Hu","year":"2013","unstructured":"Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK (2013) Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst 105(18):1417\u201320. https:\/\/doi.org\/10.1093\/jnci\/djt225","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"343_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1210\/jc.2013-3031","volume":"99","author":"P Vellanki","year":"2014","unstructured":"Vellanki P, Lange K, Elaraj D, Kopp PA, El Muayed M (2014) Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. J Clin Endocrinol Metab 99(2):387\u2013390. https:\/\/doi.org\/10.1210\/jc.2013-3031","journal-title":"J Clin Endocrinol Metab"},{"key":"343_CR14","doi-asserted-by":"publisher","unstructured":"Jumpertz von Schwartzenberg R, Elbelt U, Ventz M, Mai K, Kienitz T, Maurer L, Rose T, R\u00fcckert JC, Strasburger CJ, Spranger J (2015) Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy. Endocrinol Diabetes Metab Case Rep.150082. https:\/\/doi.org\/10.1530\/EDM-15-0082","DOI":"10.1530\/EDM-15-0082"},{"issue":"1","key":"343_CR15","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-14-0166","volume":"171","author":"D Karuppiah","year":"2014","unstructured":"Karuppiah D, Thanabalasingham G, Shine B, Wang LM, Sadler GP, Karavitaki N, Grossman AB (2014) Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. Eur J Endocrinol 171(1):K1-5. https:\/\/doi.org\/10.1530\/EJE-14-0166","journal-title":"Eur J Endocrinol"},{"issue":"22","key":"343_CR16","doi-asserted-by":"publisher","first-page":"e930301","DOI":"10.12659\/AJCR.930301","volume":"11","author":"M Kaszczewska","year":"2021","unstructured":"Kaszczewska M, Popow M, Chudzi\u0144ski W, Kaszczewska J, Bogda\u0144ska M, Podg\u00f3rska J, Czarniecka A, Ga\u0142\u0105zka Z (2021) A woman with a 27-year history of hyperparathyroidism and hypercalcemia who was diagnosed with low-grade parathyroid carcinoma. Am J Case Rep 11(22):e930301. https:\/\/doi.org\/10.12659\/AJCR.930301","journal-title":"Am J Case Rep"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00343-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-021-00343-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-021-00343-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T17:21:30Z","timestamp":1644340890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-021-00343-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1007\/s42000-021-00343-w","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"30 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that the patient provided his full consent for the publication of all his personal and medical information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}